Funding for the Translation of Regenerative Medicines

Neil J. Littman, Elona Baum, Alan O. Trounson

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review


Regenerative medicine is attracting financial investment from a diversity of sources that include countries around the globe, state agencies in the United States through novel legislative actions, and other government sources such as those associated with the U.S. armed forces. Other sources of funding for translational research for regenerative medicine include the private sector, which often aims to leverage the experience and intellectual property gained in medical and academic institutions. Private sector funding comes from a variety of sources, including pharmaceutical and biotechnology companies, venture capital investors, and institutional investors. Disease foundations are also increasingly investing in translational research, both in academia and the private sector, to deliver progress in areas of their direct interest. The degree of funding available for research is variable and often unpredictable in various countries, and research progress is often inhibited by lack of consistency as government elections change policy. There is a recognizable need for longer-term vision and support for regenerative medicine by government and industry alike to accelerate development of regenerative medicine therapies and to enhance the stability of collaborations around the globe.

Original languageEnglish
Title of host publicationTranslational Regenerative Medicine
EditorsAnthony Atala, Julie G. Allickson
Place of PublicationLondon UK
Number of pages20
ISBN (Electronic)9780124104570
ISBN (Print)9780124103962
Publication statusPublished - 2015


  • Armed forces
  • California institute for regenerative medicine
  • CIRM
  • Finance
  • Foundations
  • Funding
  • Government
  • Investment
  • National institutes of health
  • NIH
  • Private
  • Public
  • Regenerative medicine
  • Research
  • Stem cells
  • Translation
  • Venture capital

Cite this